<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326662</url>
  </required_header>
  <id_info>
    <org_study_id>FMBA OPH1</org_study_id>
    <nct_id>NCT02326662</nct_id>
  </id_info>
  <brief_title>Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury</brief_title>
  <official_title>Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novagenesis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ophiuchus Technologies AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research investigates the use of autologous neural stem cells in patients with complete&#xD;
      traumatic spinal cord injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate Mesenchymal Stem Cells [MSC]-derived autologous neural&#xD;
      stem cells transplantation as a safe and potentially beneficial treatment for patients with&#xD;
      traumatic spinal cord injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and safety of autologous Neural Stem Cell transplantation in patients with complete traumatic spinal cord injury as measured by reported side effects and surgery procedure</measure>
    <time_frame>24 months</time_frame>
    <description>Side effects is recorded by the hospital staff, in the CRF and by the patient. Surgery procedure is documented by video and standard recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>324-point ASIA and other scoring incl. muscle control and voluntary movement and improvement of sphincters control</measure>
    <time_frame>3, 6,12, 24 months and 3 year follow-up</time_frame>
    <description>Change from Baseline in ASIA Score. All patients are stable ASIA A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Scan of Spinal Cord</measure>
    <time_frame>3, 6,12, 24 months and 3 year follow-up</time_frame>
    <description>Change from Baseline of Injury Area. All patients has spinal cord injuries visible on MRI</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Paraplegics Acute</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paraplegics Sub-chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paraplegics Chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.&#xD;
Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetraplegics Acute</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetraplegics Sub-chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.&#xD;
Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetraplegics Chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation &amp; Biomatrix</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <description>Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed</description>
    <arm_group_label>Paraplegics Acute</arm_group_label>
    <arm_group_label>Paraplegics Chronic</arm_group_label>
    <arm_group_label>Paraplegics Sub-chronic</arm_group_label>
    <arm_group_label>Tetraplegics Acute</arm_group_label>
    <arm_group_label>Tetraplegics Chronic</arm_group_label>
    <arm_group_label>Tetraplegics Sub-chronic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 50 years old&#xD;
&#xD;
          -  Traumatic spinal cord injury at the neck, thoracic or lumbar level&#xD;
&#xD;
          -  Classification ASIA A and B with no significant further improvement with physical&#xD;
             therapy/rehabilitation&#xD;
&#xD;
          -  A score of less than 200 in the 324-point ASIA scale&#xD;
&#xD;
          -  Injury duration 1 month to 5 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An advanced, severe, or unstable disease of any type that may interfere with primary&#xD;
             and secondary variable evaluations, including any medical condition that could be&#xD;
             expected to progress, recur, or change to such an extent that it may bias the&#xD;
             assessment of the clinical or mental status of the patient to a significant degree or&#xD;
             put the patient at special risk (e.g., severe liver or kidney disease,&#xD;
             malignancies/cancer)&#xD;
&#xD;
          -  Immune system disorder or dysfunction&#xD;
&#xD;
          -  Any major/serious infections up to 2 months prior to inclusion&#xD;
&#xD;
          -  A disability that may prevent the patient from completing all study requirements&#xD;
             (e.g., blindness, deafness, severe language difficulty)&#xD;
&#xD;
          -  A current diagnosis of active, uncontrolled peptic ulceration within the last three&#xD;
             months&#xD;
&#xD;
          -  A current diagnosis of acute, severe, or unstable asthmatic conditions [e.g., severe&#xD;
             chronic obstructive pulmonary disease (COPD)]&#xD;
&#xD;
          -  Participated in any other investigational trial within 4 weeks of initial screening&#xD;
             and within 7 weeks of study entry&#xD;
&#xD;
          -  History of regular alcohol intake or drug abuse in the previous 3 months and not able&#xD;
             to sustain from alcohol intake during the trial Cardiovascular&#xD;
&#xD;
          -  A current diagnosis of severe or unstable cardiovascular disease&#xD;
&#xD;
          -  A current diagnosis of sick-sinus syndrome or conduction deficits (e.g., sino-atrial&#xD;
             block, second or third degree atrio-ventricular block)&#xD;
&#xD;
          -  A current diagnosis of uncontrolled atrial fibrillation (&gt;100 bpm)&#xD;
&#xD;
          -  A current diagnosis of moderate to severe heart failure [New York Heart Association&#xD;
             (NYHA), Class III or more]&#xD;
&#xD;
          -  A myocardial infarction (MI) known to have occurred within the last 3 months&#xD;
&#xD;
          -  A current diagnosis of severe or unstable angina&#xD;
&#xD;
          -  Vital signs (supine) outside the following ranges&#xD;
&#xD;
          -  Systolic blood pressure below 90 or above 160 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure below 55 or above 95 mmHg&#xD;
&#xD;
          -  Radial pulse below 50 or above 100 bpm CNS related&#xD;
&#xD;
          -  A recent history of up to one year or currently diagnosed with cerebrovascular disease&#xD;
             (e.g., stroke transient ischemic attacks, aneurysms)&#xD;
&#xD;
          -  A current diagnosis of any primary neuro-degenerative disorder [e.g., Huntington's&#xD;
             disease, Parkinson's disease etc.]&#xD;
&#xD;
          -  A current diagnosis of an active, uncontrolled seizure disorder Psychiatric&#xD;
&#xD;
          -  A current DSM-IV diagnosis of major depression&#xD;
&#xD;
          -  Any other DSM-IV Axis 1 diagnosis that may interfere with the response of the patient&#xD;
             to study medication, including other primary degenerative dementia, schizophrenia, or&#xD;
             bipolar disorder Laboratory abnormalities&#xD;
&#xD;
          -  Clinically significant abnormalities in routine laboratory examinations (hematology,&#xD;
             electrolytes, biochemistry, liver and kidney function tests, urinanalysis) Concomitant&#xD;
             therapy&#xD;
&#xD;
          -  Previous stem cell treatment&#xD;
&#xD;
          -  Ingested any of the following substances&#xD;
&#xD;
          -  An investigational drug during the past 6 months&#xD;
&#xD;
          -  A drug or treatment known to cause effect on the central nervous system [CNS] during&#xD;
             the past four weeks&#xD;
&#xD;
          -  A drug or treatment known to cause major organ system toxicity during the past four&#xD;
             weeks&#xD;
&#xD;
          -  Anticholinergic drugs at baseline&#xD;
&#xD;
          -  Medication for Parkinson's disease at baseline (e.g., selegiline, levodopa,&#xD;
             amantadine, dopamine agonists, COMT inhibitors)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Averyanov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Research Clinical Center FMBA of Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal Research Clinical Center FMBA of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>November 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>neural stem cells</keyword>
  <keyword>paraplegia</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

